Community › Results & Progress

Does anyone know why reta looks less effective for weight loss in this research paper?

15 replies12 peopleJul 16, 2026☆ Follow
Summary

Why does one network meta-analysis rank retatrutide below tirzepatide and others for weight loss despite stronger trial numbers and user results?

Participants attribute the lower ranking to the analysis omitting the most recent retatrutide data, mixing studies of unequal lengths, and applying a Bayesian model that produces results at odds with the headline trial figures. Multiple users report 24-29% losses on reta in real life, often faster than the trials cited, and view the paper as flawed or clickbait. The thread leaves open exactly why the authors chose that modeling approach.

What this discussion establishesWhere people disagree

Whether meta-analyses are inherently less trustworthy than anecdotes or individual trials.

Still open

The authors' specific rationale for the Bayesian choice and the decision not to wait for phase-3 data.

Nothing here is advice.

15 replies · 12 people
CopperLedger37archiveopening postJul 16

Anyone have an idea why reta comes out looking weaker for weight loss than tirzepatide and a few other drugs in this network meta-analysis? It goes against most of the trial numbers and personal stories I've seen. An editorial tied to it also pointed out that the review found no real edge for the injectable version of semaglutide over the pill form, even though the shot has been tied to better health results overall.

LikeSame experienceReply
SlowLedger42archiveJul 16

I hate to say it, but these days I don't put much more stock in the average research paper than in the average blog. They have nicer graphs and longer reference lists, but the quality is often missing, especially in papers that just collect and tabulate other people's results. I've seen plenty where the stated conclusions don't match the actual numbers or where simple math mistakes slipped through.

LikeSame experienceReply
AmberTimber37archiveJul 21

Does the paper line up with what people are actually seeing here? I've dropped 70 pounds on reta so far and kept it off after seven months.

LikeSame experienceReply
GreyAlder39archiveJul 21

There's just not enough reta data yet to draw firm comparisons with tirz. A comment on the article itself makes that point. We'll get more numbers later. It would be useful to gather experiences from people here. Personally I've lost 14 percent on reta in three months.

LikeSame experienceReply
CopperAlder51archiveJul 21

Everyone responds differently. Sema did nothing for me after a full year except empty my wallet. I could still eat and drink through the mild appetite effect. Reta was a completely different story and feels like a modern miracle. I've lost 78 pounds, or 29 percent of my body weight, and kept it off in 36 weeks, which beat the trial pace. I'll trust real-world results over any paper.

LikeSame experienceReply
PlainAlder11archiveJul 21
↳ replying to @CopperAlder51

I lost 55 pounds in 28 weeks, right around two pounds a week. You were at about 2.1 pounds a week. That's solid.

LikeSame experienceReply
PatientQuill81archiveJul 22

I took semaglutide for three months at the full dose and lost nothing. My wife dropped about twelve pounds before it quit working. A couple years later we both tried reta. I lost 35 pounds and she lost 20 before switching to tirz because of joint pain, then dropped another 20 on tirz. Something has to be off in that trial if reta showed no effect.

LikeSame experienceReply
CopperSignal27archiveJul 22

Without rereading the whole thing, I'm pretty sure they didn't pull in the newest reta results that showed 29 percent loss at 12 mg over 72 weeks. If they're just averaging studies without properly weighting for how long each one ran, the shorter three-to-six-month ones will drag the numbers down, while there are plenty of year-plus tirz studies to include.

LikeSame experienceReply
BrightCompass57archiveJul 22

Reta is the real deal. I only had about 30 pounds to lose total, but in the first four weeks on a low dose I've already lost nine. This stuff is pretty amazing.

LikeSame experienceReply
LevelAlder29archiveJul 22
↳ replying to @SlowLedger42

There are quite a few pay-to-play journals, but checking an author's H-index and the journal's Q-index gives a decent sense of reliability. Meta-analyses do require solid statistical skill and can be valuable when done right. The authors should spell out study limitations and how they picked which papers to include. You can twist stats to say almost anything, so looking at their methods helps, or even feeding that section to an AI for a breakdown. Peer-reviewed work still has to clear more hurdles than a blog, even if some blogs are excellent.

LikeSame experienceReply
KeenSparrow17archiveJul 22

Here we go. This one is annoying. The paper puts retatrutide at minus 13.1 percent weight loss, below tirzepatide and CagriSema. Anyone who has seen the actual trials knows reta reached around 24 percent. So how does the strongest drug land in the middle of the pack? The phase-2 obesity trial gave 24.2 percent at 12 mg after 48 weeks with no plateau yet. Tirzepatide's main trial gave 20.9 percent at 15 mg after 72 weeks. Comparing those directly, reta should rank ahead, not behind. What kind of statistical move produces this outcome?

LikeSame experienceReply
SlowLedger42archiveJul 22
↳ replying to @KeenSparrow17

But why even try a Bayesian approach in a meta-analysis like this? Unless the authors have special expertise in obesity medicine that the original trial teams lacked, they have no real basis for adjusting the numbers. If they were the top experts and the paper was meant to be definitive, maybe the adjustment would make sense, but that doesn't seem to be the case. Retatrutide is already so widely discussed that readers will just assume the authors messed up the analysis. I'm left wondering what the point was of publishing such an odd result while hiding the reasoning.

LikeSame experienceReply
KeenSparrow17archiveJul 22
↳ replying to @SlowLedger42

Exactly. I'm not sure either. I don't have enough stats background to know which model fits best. Still, it's strange that the anomaly shows up in the weight-loss percentage but not in the waist-circumference numbers. The paper does mention reta and calls the newer drugs low-certainty, saying they may produce similar or greater reductions. I agree it was a poor choice to lead with a figure that makes reta look weak based on the Bayesian run when the frequentist numbers look more reasonable, then tuck a weak note in the text. Why not just wait until the phase-3 data are out so the results would line up as expected?

LikeSame experienceReply
IronHarbour22archiveJul 22

Seems like the academic version of clickbait.

LikeSame experienceReply
AmberTimber37archiveJul 22

Down nearly 28 percent on retatrutide. It's flat-out remarkable.

LikeSame experienceReply
CopperLedger37archiveJul 23
↳ replying to @CopperSignal27

An AI model agreed that the latest data weren't used.

LikeSame experienceReply

Add your experience

If you have tried it, this topic is still open. Sign in to reply — it takes a minute.

Sign inCreate an account